Mereo BioPharma Group plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Mereo BioPharma Group plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $500.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $10.00M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 27, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.88M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($43.25M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($29.47M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($42.22M) | Mar 27, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.11M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($47.36M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($28.42M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($54.43M) | Mar 27, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.92M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $76.39M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $66.50M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $77.41M | Mar 27, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.00M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $15.42M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $15.96M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $26.01M | Mar 27, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.92M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $60.97M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $50.54M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $51.40M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $92.20M | Mar 27, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.99M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $69.80M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $57.42M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $68.18M | Mar 27, 2024 |